The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories (NYSE:FRX) under the brand name Celexa, as a potential way to help slow down the development of Alzheimer's disease.
Now this study was small and further research needs to be done, but it shows that anti-depressent use may reduce the production of beta-amyloid plaques, seen as a contributing factor for the development of Alzheimer's. However, there is a long way to go and a lot of science to discover before these common drugs are seen as a preventative tool for those at risk.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss this trial, how our knowledge of the disease is evolving and the many other new Alzheimer's treatments being developed right now.
Are you ready for this $14.4 trillion revolution?
Have you ever dreamed of traveling back in time and telling your younger self to invest in Apple? Or to load up on Amazon.com at its IPO, and then just keep holding? We haven't mastered time travel, but there is a way to get out ahead of the next big thing. The secret is to find a small-cap "pure-play" and then watch as the industry -- and your company -- enjoy those same explosive returns. Our team of equity analysts has identified one stock that's ready for stunning profits with the growth of a $14.4 TRILLION industry. You can't travel back in time, but you can set up your future. Click here for the whole story in our eye-opening report.
David Williamson owns shares of Johnson & Johnson and Merck. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.